Financials

v3.7.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2017
Dec. 31, 2016
Current Assets    
Cash and cash equivalents $ 13,471 $ 19,055
Prepaid expenses and other current assets 3,366 2,515
Total Current Assets 16,837 21,570
Property and equipment, net 859 905
Deposits and other assets 23 23
Total Assets 17,719 22,498
Current Liabilities:    
Accounts payable 3,796 1,993
Accrued expenses 2,134 2,627
Warrant liabilities 9,731 14,821
Accrued employee benefits 787 313
Deferred rent 40 3
Total Current Liabilities 16,488 19,757
Long term deferred rent 470 492
Total Liabilities 16,958 20,249
Commitments and Contingencies
Stockholders’ Equity:    
Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding 0 0
Common stock, $0.001 par value; 250,000,000 shares authorized, 118,017,693 issued and 117,936,211 outstanding and 117,254,196 issued and 117,172,714 outstanding, respectively 118 117
Additional paid-in capital 177,331 175,762
Accumulated deficit (174,880) (172,034)
Total Synthetic Biologics, Inc. and Subsidiaries Equity 2,569 3,845
Non-controlling interest (1,808) (1,596)
Total Stockholders’ Equity 761 2,249
Total Liabilities and Stockholders' Equity $ 17,719 $ 22,498

Source

v3.7.0.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Operating Costs and Expenses:    
General and administrative $ 2,090 $ 2,426
Research and development 6,059 8,155
Total Operating Costs and Expenses 8,149 10,581
Loss from Operations (8,149) (10,581)
Other Income (Expense):    
Change in fair value of warrant liability 5,090 (498)
Interest income 1 1
Total Other Income (Expense) 5,091 (497)
Net Loss (3,058) (11,078)
Net Loss Attributable to Non-controlling Interest (212) (233)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries $ (2,846) $ (10,845)
Net Loss Per Share - Basic and Dilutive $ (0.02) $ (0.12)
Weighted average number of shares outstanding during the period - Basic and Dilutive 117,447,260 90,826,752

Source

v3.7.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Cash Flows From Operating Activities:    
Net Loss $ (3,058) $ (11,078)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation 1,135 1,052
Change in fair value of warrant liabilities (5,090) 498
Depreciation 57 37
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (851) 2,403
Deposits and other assets 0 (12)
Accounts payable 1,803 184
Accrued expenses (493) 649
Accrued employee benefits 474 592
Deferred rent 15 1
Net Cash Used In Operating Activities (6,008) (5,674)
Cash Flows From Investing Activities:    
Purchases of property and equipment (11) (44)
Net Cash Used In Investing Activities (11) (44)
Cash Flows From Financing Activities:    
Proceeds from issuance of common stock from stock option exercises 166 0
Proceeds from “at the market” stock issuance 269 0
Net Cash Provided By Financing Activities 435 0
Net decrease in cash (5,584) (5,718)
Cash at beginning of period 19,055 20,818
Cash at end of period 13,471 15,100
Supplemental disclosures of cash flow information:    
Cash paid for interest 0 0
Cash paid for taxes $ 0 $ 0

Source